News - 漢康生技

HanchorBio and NYCU Launch AI-Enabled Drug Discovery Collaboration to Advance Next-Generation Biologics

HanchorBio started a research collaboration with the College of Engineering Bioscience at National Yang Ming Chiao Tung University (NYCU) to advance AI-enabled biologics discovery.

Apr 29, 2026

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

HanchorBio announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.

Apr 24, 2026

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

HanchorBio announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.

Apr 24, 2026

HanchorBio Presents Early Frontline Triple-Negative Breast Cancer Data for HCB101 Combination at GBCC 2026

HanchorBio announced the first dedicated presentation of HCB101 clinical data from an ongoing study evaluating HCB101 in combination with anti-PD-1 and nab-paclitaxel in patients with advanced triple-negative breast cancer (TNBC) at the Global Breast Cancer Conference 2026 (GBCC 2026) in Seoul, Korea.

Apr 23, 2026

HanchorBio Reports Head and Neck Cancer Data for HCB101, Including Durable Monotherapy Activity and Complete Response at Low Dose in Combination with PD-1

HanchorBio reported updated clinical observations in head and neck squamous cell carcinoma (HNSCC) across both monotherapy and combination settings for HCB101, its rationally engineered SIRPα-Fc fusion protein functioning as an innate immune checkpoint blockade.

Apr 22, 2026

HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation

HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.

Apr 20, 2026

HanchorBio Announces Successful Completion of First 2,000L GMP Clinical Batch Production of HCB101

HanchorBio's HCB101, one of its core FBDB™ (Fc-Based Designer Biologics) oncology pipeline assets, has successfully completed its first GMP clinical batch production scaled up from a 500L to a 2,000L bioreactor. This production was carried out at WuXi Biologics’ manufacturing facility, covering the full process from Drug Substance (DS) to Drug Product (DP), and achieved all predefined manufacturing objectives.

Apr 14, 2026

HanchorBio Invited to Participate in the 19th QIC CEO Week

HanchorBio has been invited to participate in the 19th QIC CEO Week to meet with international institutional investors in Singapore to share corporate progress and strategic priorities.

Apr 13, 2026

HanchorBio Doses First Patient in Taiwan in Phase 1 Trial of HCB301

HanchorBio today announced that the first patient in Taiwan has been dosed in HCB301-101, the Company’s ongoing first-in-human Phase 1 clinical study of HCB301.

Apr 08, 2026

HanchorBio Signals “Backbone” Potential for HCB101 as SAB Aligns on Gastric Cancer Registrational Path

HanchorBio reported outcomes from its recent Scientific Advisory Board (SAB) meeting, highlighting a shift from platform validation to asset-level positioning and registrational strategy.

Apr 03, 2026